Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selatogrel - Idorsia Pharmaceuticals

Drug Profile

Selatogrel - Idorsia Pharmaceuticals

Alternative Names: ACT-246475

Latest Information Update: 30 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Anti-ischaemics; Cardiovascular therapies; Piperazines; Pyrimidines; Pyrrolidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Coronary artery disease; Myocardial infarction
  • No development reported Cardiovascular disorders

Most Recent Events

  • 19 Nov 2019 Idorsia Pharmaceuticals and Antares Pharma enter into a agreement to develop selatogrel drug-device combination product
  • 19 Nov 2019 Idorsia Pharmaceuticals plans a global phase III trial Myocardial infraction in the first half of 2021
  • 03 Sep 2019 Efficacy and adverse events data from a phase II trial in Coronary artery disease presented at the European Society of Cardiology (ESC-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top